Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

JARID2 antibody (AA 1-159)

JARID2 Reactivity: Human ELISA, IHC, IF Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN7165672
  • Target See all JARID2 Antibodies
    JARID2 (Jumonji, AT Rich Interactive Domain 2 (JARID2))
    Binding Specificity
    • 15
    • 6
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 1-159
    Reactivity
    • 42
    • 16
    • 11
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Host
    • 33
    • 9
    • 2
    • 1
    Rabbit
    Clonality
    • 36
    • 9
    Polyclonal
    Conjugate
    • 20
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    This JARID2 antibody is un-conjugated
    Application
    • 32
    • 13
    • 13
    • 11
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)
    Cross-Reactivity
    Human
    Purification
    >95%, Protein G purified
    Immunogen
    Recombinant Human Protein Jumonji protein (1-159AA)
    Isotype
    IgG
    Top Product
    Discover our top product JARID2 Primary Antibody
  • Application Notes
    Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C,-80 °C
    Storage Comment
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    JARID2 (Jumonji, AT Rich Interactive Domain 2 (JARID2))
    Alternative Name
    JARID2 (JARID2 Products)
    Synonyms
    JMJ antibody, Jmj antibody, jumonji antibody, JARID2 antibody, jarid2 antibody, jmj antibody, si:dkey-211c3.1 antibody, Jumonji antibody, jarid2-a antibody, jarid2-b antibody, jarid2.S antibody, jarid2b antibody, jumonji and AT-rich interaction domain containing 2 antibody, jumonji, AT rich interactive domain 2 antibody, jumonji, AT rich interactive domain 2a antibody, jumonji, AT rich interactive domain 2b antibody, jumonji and AT-rich interaction domain containing 2 L homeolog antibody, JARID2 antibody, Jarid2 antibody, jarid2a antibody, jarid2 antibody, jarid2b antibody, jarid2.L antibody
    Background

    Background: Regulator of histone methyltransferase complexes that plays an essential role in embryonic development, including heart and liver development, neural tube fusion process and hematopoiesis. Acts by modulating histone methyltransferase activity and promoting the recruitment of histone methyltransferase complexes to their target genes. Binds DNA and mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells. Does not have histone demethylase activity but regulates activity of various histone methyltransferase complexes. In embryonic stem cells, it associates with the PRC2 complex and inhibits trimethylation of \\\'Lys-27\\\' of histone H3 (H3K27me3) by the PRC2 complex, thereby playing a key role in differentiation of embryonic stem cells and normal development. In cardiac cells, it is required to repress expression of cyclin-D1 (CCND1) by activating methylation of \\\'Lys-9\\\' of histone H3 (H3K9me) by the GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases. Also acts as a transcriptional repressor of ANF via its interaction with GATA4 and NKX2-5. Participates in the negative regulation of cell proliferation signaling.

    Aliases: JARD2 antibody, JARD2_HUMAN antibody, JARID2 antibody, JMJ antibody, Jumonji AT rich interactive domain 2 antibody, Jumonji homolog antibody, Jumonji like protein antibody, Jumonji protein antibody, Jumonji/ARID domain containing protein 2 antibody, Jumonji/ARID domain-containing protein 2 antibody, Protein Jumonji antibody

    UniProt
    Q92833
    Pathways
    Chromatin Binding
You are here: